Dr. Mark S. Womack IV, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 746
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Tennessee, Hsc, College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license MD0000047306
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Healthcare System, Inc Chattanooga, TN
- Erlanger Medical Center Chattanooga, TN
- Parkridge Medical Center Chattanooga, TN
Medical groups
- Tennessee Oncology PLLC (358 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 746
- Services billed
- 189,301
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 39,000 | 29 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 27,000 | 30 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 24,120 | 15 |
| Injection, pembrolizumab, 1 mg | 21,000 | 14 |
| Injection, oxaliplatin, 0.5 mg | 16,800 | 17 |
| Injection, denosumab, 1 mg | 5,580 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,676 | 70 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 2,319 | 545 |
| Insertion of needle into vein for collection of blood sample | 1,824 | 521 |
| Blood test, comprehensive group of blood chemicals | 1,696 | 492 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Chattanooga, TN | 140 |
| Abiraterone Acetate | 116 |
| Prochlorperazine Maleate Other prescribers in Chattanooga, TN | 94 |
| Eliquis (apixaban) Other prescribers in Chattanooga, TN | 84 |
| Ondansetron Hcl Other prescribers in Chattanooga, TN | 80 |
| Acyclovir Other prescribers in Chattanooga, TN | 69 |
| Revlimid (lenalidomide) | 68 |
| Ondansetron Odt (ondansetron) Other prescribers in Chattanooga, TN | 67 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Chattanooga, TN | 63 |
| Calquence (acalabrutinib maleate) | 61 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 11 payments worth $274 in total to this clinician.
| Aveo Pharmaceuticals, Inc. | $61.74 |
|---|---|
| Novartis Pharmaceuticals Corporation | $48.06 |
| AbbVie Inc. | $38.65 |
| Merck Sharp & Dohme LLC | $34.70 |
| Eisai Inc. | $30.64 |
| Servier Pharmaceuticals LLC | $20.68 |
| GlaxoSmithKline, LLC. | $19.98 |
| Celgene Corporation | $19.78 |
| Food and Beverage | $254 |
|---|---|
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Apr 8, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $31,714 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Ipsen Bioscience Inc. · Completed · NCT04083235 - A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Exelixis Inc. - Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.